Regulation of bovine endometrial secretion of prostaglandins and synthesis of 2',5'-oligoadenylate synthetase by interferon-alpha molecules.
Experiments were performed to (1) verify the inhibitory effect of bovine trophoblast protein-1 (bTP-1) on uterine prostaglandin synthesis, (2) evaluate whether other interferon-alpha (IFN-alpha) molecules also inhibit prostaglandin secretion, and (3) test whether the enzyme 2',5'-oligoadenylate synthetase (2-5A synthetase) can be induced in endometrium by interferon-alpha. In experiment 1, all interferon molecules (bTP-1, oTP-1, bIFN-alpha and hIFN-alpha) equally inhibited secretion of PGF and PGE2 from endometrial explant cultures obtained at day 17 of the estrous cycle. In experiment 2, endometrial explants obtained from day 17 of the cycle were cultured with and without bovine serum albumin (BSA; 50 micrograms/ml) and bIFN-alpha (0, 0.84, 4.2, and 42 nM). Addition of BSA to the culture medium greatly enhanced the accumulation of PGF into the medium. The bIFN-alpha inhibited accumulation of PGF and PGE2 in both the presence or absence of BSA by 12 h. All three concentrations of bIFN-alpha were equally effective in inhibiting prostaglandin accumulation. Additionally, all concentrations of bIFN-alpha increased the amounts of 2-5A synthetase in endometrium. In conclusion, these results confirm the inhibitory effect of bTP-1 on PGF release from endometrium and demonstrate that bTP-1 can also inhibit PGE2 secretion. Furthermore, other interferon-alpha molecules, including bIFN-alpha, hIFN-alpha, and oTP-1, also reduced PGF and PGE2 secretion in culture. It is likely, therefore, that conceptus and other interferon-alpha molecules exert similar effects on endometrium in vitro and that the antiluteolytic effects of bIFN-alpha in vivo are mediated in part by changes in endometrial prostaglandin synthesis.
Barros
C M
CM
Departamento de Farmacologia, Universidade Estadual Paulista, Sao Paulo, Brasil.
Plante
C
C
Thatcher
W W
WW
Hansen
P J
PJ
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism*; D000818:Animals; D002417:Cattle; D003338:Corpus Luteum / Q000187:drug effects; D046508:Culture Techniques; D015237:Dinoprost / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004717:Endometrium / Q000378:metabolism*; D005260:Female; D005786:Gene Expression Regulation; D007370:Interferon Type I; D016898:Interferon-alpha / Q000494:pharmacology*; D008186:Luteolytic Agents / Q000037:antagonists & inhibitors; D011257:Pregnancy Proteins / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism*; D011994:Recombinant Proteins / Q000494:pharmacology; D012709:Serum Albumin / Q000494:pharmacology
D007370:Interferon Type I; D016898:Interferon-alpha; D008186:Luteolytic Agents; D011257:Pregnancy Proteins; D011453:Prostaglandins; D011994:Recombinant Proteins; D012709:Serum Albumin; C020947:interferon tau; D015237:Dinoprost; D015088:2',5'-Oligoadenylate Synthetase; D015232:Dinoprostone